PharmaRoth Labs, Inc. (ROTH)

[sweetlou]

"...a typical IR play to make money selling stock not product"
Please provide specific evidence of this claim.

The stock sales are listed in the quarterly and annual reports, as are the sales of product and the costs of manufacturing and distribution etc. How, exactly, in light of that, is the company making money from selling stock, any more than to meet expenses and production of Sucanon for distribution? What, exactly, is the evidence for the previous claim that "hundreds of millions of shares printed at zero cost basis" when at last report some 317 million shares total were outstanding? Where is the "pump" claimed so vividly? The promoters?
If the FDA application was just for a news release, where was the dilution of dump surrounding that announcement? For that matter, why put out information for a "pump" that states the company cannot sell Sucanon in the US as a Neutraceutical? While the acknowledgment that Sucanon should be considered a drug for US application, that cuts both ways in that a significant expense would be required to bring it to market. Not IMO a piece of news that will cause an immediate unjustified spike in stock price.
I have laid out my argument with the science of Sucanon studies. Let's see some cold hard facts on the above so they can be evaluated by any here that are interested